Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

PACIRA BIOSCIENCES, INC.

(PCRX)
  Report
Real-time Estimate Cboe BZX  -  02:06 2022-11-28 pm EST
49.23 USD   -0.94%
11/15Sector Update: Health Care Stocks Edge Higher Premarket Tuesday
MT
11/15Pacira BioSciences Reports Higher Exparel Preliminary Net Product Sales in October; Wedbush Maintains Forecast
MT
11/14Pacira BioSciences Reports Higher Exparel Preliminary Net Product Sales in October
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Days
:
Hours
:
Minutes
:
Seconds
Valuation
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Capitalization1 1 8902 6002 6802 280--
Enterprise Value (EV)1 2 1182 9623 1442 7902 5282 240
P/E ratio -168x18,0x65,4x51,9x23,6x17,5x
Yield ------
Capitalization / Revenue 4,49x6,05x4,95x3,37x2,93x2,62x
EV / Revenue 5,03x6,89x5,81x4,12x3,25x2,57x
EV / EBITDA 22,3x26,3x15,4x12,2x7,67x5,39x
Price to Book 5,35x4,21x3,69x2,74x2,19x1,74x
Nbr of stocks (in thousands) 41 73143 44444 54445 882--
Reference price (USD) 45,359,860,249,749,749,7
Announcement Date 02/20/202002/25/202102/24/2022---
1 USD in Million
Previous periodNext period
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales1 421430542677777871
EBITDA1 94,9113204228330415
Operating profit (EBIT)1 75,399,3189209305386
Operating Margin 17,9%23,1%34,9%30,9%39,2%44,3%
Pre-Tax Profit (EBT)1 -10,720,156,460,9148185
Net income1 -11,014642,047,0102129
Net margin -2,62%33,9%7,75%6,94%13,1%14,8%
EPS2 -0,273,330,920,962,112,84
Dividend per Share ------
Announcement Date 02/20/202002/25/202102/24/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2
Net sales1 158169167182181192
EBITDA1 53,844,955,273,8--
Operating profit (EBIT)1 49,240,950,868,463,078,5
Operating Margin 31,1%24,1%30,3%37,5%34,7%40,9%
Pre-Tax Profit (EBT)1 7,2922,02,0729,54,334,23
Net income1 6,8319,9-0,6921,03,153,05
Net margin 4,32%11,7%-0,41%11,5%1,74%1,59%
EPS2 0,150,40-0,020,420,450,48
Dividend per Share ------
Announcement Date 05/04/202208/03/202211/03/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt1 228363464510248-
Net Cash position1 -----40,2
Leverage (Debt / EBITDA) 2,40x3,22x2,27x2,24x0,75x-0,10x
Free Cash Flow1 69,573,079,938,1213257
ROE (Net Profit / Equities) 20,9%19,8%20,2%18,7%24,2%24,4%
Shareholders' equity1 -52,7734207251421529
ROA (Net Profit / Asset) 9,30%9,17%8,16%7,58%12,0%13,6%
Assets1 -1181 586514620846947
Book Value Per Share2 8,4714,216,318,122,728,6
Cash Flow per Share ------
Capex1 10,237,845,922,533,634,3
Capex / Sales 2,41%8,80%8,47%3,32%4,33%3,93%
Announcement Date 02/20/202002/25/202102/24/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Key data
Capitalization (USD) 2 279 880 952
Net sales (USD) 541 533 000
Number of employees 697
Sales / Employee (USD) 776 948
Free-Float 98,9%
Free-Float capitalization (USD) 2 253 668 732
Avg. Exchange 20 sessions (USD) 22 989 315
Average Daily Capital Traded 1,01%
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA